FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1560691946> ?p ?o ?g. }

• W1560691946 endingPage "313" @default.
• W1560691946 startingPage "303" @default.
• W1560691946 abstract "BACKGROUND It is timely and important to develop new treatment modalities for advanced prostate cancer, because even the newly FDA approved treatments, despite providing significant survival benefits, do not constitute cure of this disease. Antibody drug conjugates (ADCs) represent a promising approach to cancer therapy. Prostate‐specific membrane antigen (PSMA) is expressed in advanced prostate cancer and targeting this protein is used for imaging of advanced prostate cancer as well as development of targeting strategies. The objective of our studies was to evaluate the efficacy of PSMA ADC against a series of patient‐derived prostate cancer xenografts (LuCaP 58, LuCaP 77, LuCaP 96CR, and LuCaP 105) with different characteristics, including varying levels of PSMA expression and responses to androgen suppression. METHODS Mice bearing subcutaneous LuCaP prostate cancer‐derived xenografts received PSMA antibody monomethyl auristatin E (MMAE) drug conjugate (PSMA ADC) in which the antibody and MMAE are linked via a protease‐cleavable linker. PSMA ADC dose ranged from 1 to 6 mg/kg. Unmodified PSMA mAb + free MMAE at the amount equivalent to those contained in 6 mg/kg PSMA ADC was used as control. All treatments were administered once a week via tail‐vein injections and repeated four times once a week and tumor responses were monitored for 10 weeks. IHC analyses were performed to determine PSMA and AR expression and effects on proliferation. RESULTS Treatment responses varied widely across the tumor models, from complete tumor regressions in LuCaP 96CR to largely unimpeded tumor progression of LuCaP 58, which had the lowest baseline level of PSMA expression. Intermediate antitumor effects were seen for LuCaP 77 and LuCaP 105 tumors, despite their having similar basal expression of PSMA as LuCaP 96CR. Interestingly, we detected substantial differences in responses even within the same model, indicating that PSMA expression is not the only factor involved in treatment outcomes. CONCLUSIONS Our results show high efficacy of PSMA ADC in advanced prostate cancer but also considerable variability in effects despite PSMA expression. Further studies to identify tumor characteristics that are predictive of treatment response are ongoing. Prostate 75:303–313, 2015 . © 2014 Wiley Periodicals, Inc." @default.
• W1560691946 created "2016-06-24" @default.
• W1560691946 creator A5002466627 @default.
• W1560691946 creator A5017367178 @default.
• W1560691946 creator A5017807897 @default.
• W1560691946 creator A5018745405 @default.
• W1560691946 creator A5057037633 @default.
• W1560691946 creator A5088583553 @default.
• W1560691946 date "2014-10-18" @default.
• W1560691946 modified "2023-10-18" @default.
• W1560691946 title "Efficacy studies of an antibody-drug conjugate PSMA-ADC in patient-derived prostate cancer xenografts" @default.
• W1560691946 cites W1795111525 @default.
• W1560691946 cites W1968302410 @default.
• W1560691946 cites W1981421409 @default.
• W1560691946 cites W2011118089 @default.
• W1560691946 cites W2013984021 @default.
• W1560691946 cites W2014303129 @default.
• W1560691946 cites W2019766823 @default.
• W1560691946 cites W2023679944 @default.
• W1560691946 cites W2024001437 @default.
• W1560691946 cites W2027279302 @default.
• W1560691946 cites W2034428193 @default.
• W1560691946 cites W2034609970 @default.
• W1560691946 cites W2045892715 @default.
• W1560691946 cites W2051025382 @default.
• W1560691946 cites W2056112452 @default.
• W1560691946 cites W2072304925 @default.
• W1560691946 cites W2077470692 @default.
• W1560691946 cites W2090057677 @default.
• W1560691946 cites W2104998312 @default.
• W1560691946 cites W2108337681 @default.
• W1560691946 cites W2109937560 @default.
• W1560691946 cites W2112083044 @default.
• W1560691946 cites W2113529846 @default.
• W1560691946 cites W2113720647 @default.
• W1560691946 cites W2113991862 @default.
• W1560691946 cites W2116569478 @default.
• W1560691946 cites W2132696220 @default.
• W1560691946 cites W2141105945 @default.
• W1560691946 cites W2159967578 @default.
• W1560691946 cites W2314074415 @default.
• W1560691946 cites W4248620601 @default.
• W1560691946 doi "https://doi.org/10.1002/pros.22916" @default.
• W1560691946 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25327986" @default.
• W1560691946 hasPublicationYear "2014" @default.
• W1560691946 type Work @default.
• W1560691946 sameAs 1560691946 @default.
• W1560691946 citedByCount "33" @default.
• W1560691946 countsByYear W15606919462014 @default.
• W1560691946 countsByYear W15606919462015 @default.
• W1560691946 countsByYear W15606919462016 @default.
• W1560691946 countsByYear W15606919462017 @default.
• W1560691946 countsByYear W15606919462018 @default.
• W1560691946 countsByYear W15606919462019 @default.
• W1560691946 countsByYear W15606919462020 @default.
• W1560691946 countsByYear W15606919462021 @default.
• W1560691946 countsByYear W15606919462023 @default.
• W1560691946 crossrefType "journal-article" @default.
• W1560691946 hasAuthorship W1560691946A5002466627 @default.
• W1560691946 hasAuthorship W1560691946A5017367178 @default.
• W1560691946 hasAuthorship W1560691946A5017807897 @default.
• W1560691946 hasAuthorship W1560691946A5018745405 @default.
• W1560691946 hasAuthorship W1560691946A5057037633 @default.
• W1560691946 hasAuthorship W1560691946A5088583553 @default.
• W1560691946 hasConcept C121608353 @default.
• W1560691946 hasConcept C126322002 @default.
• W1560691946 hasConcept C134306372 @default.
• W1560691946 hasConcept C143998085 @default.
• W1560691946 hasConcept C159654299 @default.
• W1560691946 hasConcept C197336794 @default.
• W1560691946 hasConcept C203014093 @default.
• W1560691946 hasConcept C20417620 @default.
• W1560691946 hasConcept C2776235491 @default.
• W1560691946 hasConcept C2777325958 @default.
• W1560691946 hasConcept C2780192828 @default.
• W1560691946 hasConcept C33923547 @default.
• W1560691946 hasConcept C502942594 @default.
• W1560691946 hasConcept C542903549 @default.
• W1560691946 hasConcept C71924100 @default.
• W1560691946 hasConceptScore W1560691946C121608353 @default.
• W1560691946 hasConceptScore W1560691946C126322002 @default.
• W1560691946 hasConceptScore W1560691946C134306372 @default.
• W1560691946 hasConceptScore W1560691946C143998085 @default.
• W1560691946 hasConceptScore W1560691946C159654299 @default.
• W1560691946 hasConceptScore W1560691946C197336794 @default.
• W1560691946 hasConceptScore W1560691946C203014093 @default.
• W1560691946 hasConceptScore W1560691946C20417620 @default.
• W1560691946 hasConceptScore W1560691946C2776235491 @default.
• W1560691946 hasConceptScore W1560691946C2777325958 @default.
• W1560691946 hasConceptScore W1560691946C2780192828 @default.
• W1560691946 hasConceptScore W1560691946C33923547 @default.
• W1560691946 hasConceptScore W1560691946C502942594 @default.
• W1560691946 hasConceptScore W1560691946C542903549 @default.
• W1560691946 hasConceptScore W1560691946C71924100 @default.
• W1560691946 hasIssue "3" @default.
• W1560691946 hasLocation W15606919461 @default.
• W1560691946 hasLocation W15606919462 @default.
• W1560691946 hasOpenAccess W1560691946 @default.

• next